All News

Analyzing consolidation of 8 drug pump libraries into 1 IV infusion library in a 9-hospital system: from standardization to implementation.

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 trial.

Eosinophilic granulomatosis with polyangiitis is a rare and immune-mediate vasculitis that can damage multiple organs and be fatal if left untreated.

The treatment significantly reduced risk of occurrence by 25% compared with endocrine therapy alone.

Ten-year follow up data showed a sustained survival benefit with nivolumab-ipilimumab in advanced melanoma.

Eversense 365 (Senseonics) is the first long-lasting continuous glucose monitoring (CGM) system, which includes a 365-day sensor and only 1 insertion on Day 1 of every year.

Implementation of yearly mock code training can reinforce essential knowledge and increase pharmacists’ clinical competence and confidence when faced with actual neonatal and pediatric emergencies.

In 2021, cancer diagnosis rates remained low after major disruptions during the first year of the COVID-19 pandemic.

Different drug products require varying approaches to handle access challenges and ensure continuation of care.

Pharmacy students discuss the value of collaborative, hands-on learning approaches that leverage technology and social media to enhance learning.

A centralized, artificial intelligence–driven approach can integrate diverse data and foster multidisciplinary collaboration.

The trial demonstrated that the combination of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) significantly improves progression-free survival and objective response rates compared to TACE alone.

The efficacy and safety profiles of CAR T-cell and bispecific antibody therapies have led to their investigation in earlier lines of therapy, with several new treatments in development.

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

There is a need for continued research and awareness in the diagnosis and management of alopecia in diverse populations.

The non-opioid drug can induce healing of joint cartilage in patients with osteoarthritis.

With the end of the PREP Act provisions approaching, we want to understand how pharmacists feel about their scopes of practice in each state, and what they think about the future of the profession.

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.

Abstracts from the OrigAMI-1 and MARIPOSA-2 trials indicated the treatment benefits of amivantamab-vmjw and chemotherapy in multiple cancer indications.

Pharmacists can help identify potential drug-drug interactions and adverse reactions, and advise patients when to seek further treatment

At ESMO Congress 2024, Shuji Ogino, MD, PhD, MS, explained that the rising incidence of young-onset cancer may be due to generational risk factors such as lifestyle, diet, and environmental changes, emphasizing the need for long-term research and follow up to understand early-life influences on cancer development.

With the introduction of expensive drugs and associated challenges for hospital budgets, pharmacy leaders benefit from strategically managing financial, clinical, and regulatory factors for sustainable care delivery.

Incorporating AI into pharmacy education is crucial to training on its appropriate use.

Two groundbreaking cell-based gene therapies, exagamglogene autotemcel and lovotibeglogene autotemcel, were recently approved by the FDA for the treatment of sickle cell disease.

Pharmacists’ role in community-based cancer centers are expanding, with a more significant role in treatment plan selection, education, collaboration to create individualized care plans, managing adverse effects, and aiding with financial toxicities.

Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.